Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 112

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 112
---
 emerging growth company. We would cease to be an emerging
growth company upon the earliest to occur of: (i) the last day of the fiscal year in which we have total annual gross revenues of
$1.235 billion or more; (ii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the
previous three years; (iii) the date on which we are deemed to be a large accelerated filer under the rules of the SEC; or (iv) the
last day of the fiscal year following the fifth anniversary of this offering. We may choose to take advantage of some but not all of these
exemptions. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended
transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This
means that an “emerging growth company” can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised
accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of
the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as
other public companies that are not emerging growth companies which may make comparison of our financials to those of other public companies
more difficult.

Liquidity and Capital Resources

Since our inception,
we have incurred losses and negative cash flows from our operations. For the year ended December 31, 2024, we had an income of $5.2
million (which was mainly due to the Horizon 2020 Grant and finance income from revaluation of our convertible motes and warrant
liability) and net cash of $0.6 million was used in our operating activities. As of December 31, 2024 and December 31, 2023, we had
a negative working capital of $5.5 million and $2.8 million, respectively, and an accumulated deficit of approximately
$41.7 million and $46.9 million, respectively. As of December 31, 2024, our cash and cash equivalents totaled approximately
$0.2 million. We believe that after the completion of this offering our cash and cash equivalents, including the proceeds from
this offering, will enable